RAPAMYCIN
MODERATE
▲ +3 papers · 7d
METFORMIN
MODERATE
▲ +1 paper · 7d
NMN
EMERGING
▲ +6 papers · 7d
NR
EMERGING
▲ +2 papers · 7d
D + Q
EMERGING
▲ +12 papers · 7d
GLP-1 AGONISTS
STRONG
▲ +7 papers · 7d
SGLT2 INHIBITORS
STRONG
ACARBOSE
MODERATE
TAURINE
EMERGING
BERBERINE
EMERGING
17Α-ESTRADIOL
EMERGING
SPERMIDINE
EMERGING
▲ +2 papers · 7d
UROLITHIN A
EMERGING
▲ +1 paper · 7d
FISETIN
EMERGING
GLYNAC
EMERGING
RAPAMYCIN
MODERATE
▲ +3 papers · 7d
METFORMIN
MODERATE
▲ +1 paper · 7d
NMN
EMERGING
▲ +6 papers · 7d
NR
EMERGING
▲ +2 papers · 7d
D + Q
EMERGING
▲ +12 papers · 7d
GLP-1 AGONISTS
STRONG
▲ +7 papers · 7d
SGLT2 INHIBITORS
STRONG
ACARBOSE
MODERATE
TAURINE
EMERGING
BERBERINE
EMERGING
17Α-ESTRADIOL
EMERGING
SPERMIDINE
EMERGING
▲ +2 papers · 7d
UROLITHIN A
EMERGING
▲ +1 paper · 7d
FISETIN
EMERGING
GLYNAC
EMERGING
Vol.
I
· No.
33
Thursday, August 13, 2026
Issue:
Summer · 2026
Established · MMXXVI
Geroevidence
— The evidence base for longevity medicine —
Indexed by
PubMed
·
CTG
·
Cochrane
Editorial team ·
geroevidence.com
Subscription ·
app.geroevidence.com
Home
Interventions
Evidence
Blog
About
Roadmap
Pricing
Sign in
Start free trial →
Geroevidence
·
Editorial desk
·
Clinical Trials
Clinical Trials
Trial readouts, protocol analyses, and enrollment updates.
16 articles in this category
·
← All categories
§ Clinical Trials · 16 articles · page 2 of 2
The TAME trial explained: what metformin's biggest longevity test will actually tell us
TAME is the most significant longevity trial running. What the trial design means, what a positive result would and would not prove, and what interim signals look like.
May 10, 2026 · 11 min read
← Newer
Page 2 of 2